- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02099214
Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis (HEMOCOEUR)
Estimation of Myocardial Iron Overload by 3 Tesla MRI and Cardiac Functional Consequences in Patients With HFE Hereditary Haemochromatosis. Pilot Study
Hereditary haemochromatosis (HHC) is a frequent disease in Brittany (5 to 7‰), responsible first for biological disorder in blood iron parameters and minor clinical disorders, before evolving to potential life-threatening consequences such as diabetes, liver cirrhosis and congestive heart failure.
The improvement of screening and treatments made those severe affections rare enough not to evaluate myocardial iron overload a systematic part of the starting check-up. Nonetheless this myocardial iron overload might have severe implications on cardiac function on a long term basis.
A single trial was conducted on limited number of patients with 1.5 Tesla MRI, which showed a myocardial iron overload (defined by a myocardium T2* value <20ms) in 19% of the subjects.
The main objective of this study is to precisely estimate cardiac iron overload in treatment naive patients with newly diagnosed HFE hereditary haemochromatosis with a 3 Tesla MRI, more sensitive than the 1.5 Tesla one, in order to later appreciate its correlation with cardiac morbidity in HHC.
Study Overview
Status
Detailed Description
Since the wide use of phlebotomy was implemented the incidence of congestive heart failure in HHC became quite low. As such, the interest towards the initial diagnosis and cardiological follow-up has been lesser. A subclinical myocardial iron overload can nevertheless exist and eventually lead to functional consequences in the medium and long term if neglected, even evolve into heart failure and preserved ejection fraction.
The expected aftermath of this study is :
- The estimation of the frequency of myocardial iron overload measured by 3 Tesla MRI in patient with HFE hereditary haemochromatosis;
- The assessment of its consequences on heart function;
- The appreciation of a cardiological assessment strategy in patients with HFE hereditary haemochromatosis.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Rennes, France, 35000
- Rennes University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients :
- Adults older than 18 ;
- Newly diagnosed with HFE hereditary haemochromatosis by genetic testing (homozygous for the C283Y mutation on HFE gene);
- Treatment-naive;
- Showing a ferritin level higher than 200µg/l for women and higher than 300µg/L for men;
- Affiliated to French Social Security;
- Having given a written informed consent.
Healthy volunteers:
- Adults older than 18;
Presenting all the following criterions:
- Normal cardiovascular physical examination: no signs of cardiac insufficiency, no pathological cardiac murmur, normal EKG (regular sinus rhythm, no high degree AV nor ventricular blocks, no rhythm anomaly),
- Body Mass Index <27 kg/m²,
- Normal routine blood biology (blood count, MCV, serum iron, ferritin, transferrin saturation);
- Affiliated to French Social Security;
- Having given a written informed consent.
Exclusion Criteria:
Patients :
MRI-related criterions :
- Cardiac pacemaker or implanted defibrillator ;
- Non MRI-compatible prosthetic cardiac valve;
- Non MRI-compatible clips/stents/coils/etc.;
- Cochlear implant;
- Peripheral or neuronal stimulator;
- Intra-ocular or brain metallic foreign bodies , foreign body in the eyes' vicinity, shrapnel or firearm wound;
- Less than 4 weeks-old stents, less than 6 weeks-old osteosynthesis materials;
- Claustrophobia;
- Pumps, tattoos, permanent makeup, intrauterine device, patches;
- Non-removable metallic or magnetic material in the vicinity of the analysed field.
Other criterions :
- Haemodynamic instability / Acute respiratory insufficiency / Altered general status / Need for continuous monitoring incompatible wih MRI confines;
- Pregnancy, breast feeding;
- History of blood transfusion or iron supplementation;
- Blood donation in the last 3 months;
- Infection in the 7 days prior to the first visit;
- Stay in altitude (>1500m) in the past 2 months;
- Adults under legal protective regimen or deprived of liberty.
Healthy volunteers
- Alcohol abuse (>20g per day for women, >30g per day for men);
- Active tobacco intoxication or smoking cessation in the 6 last months;
- Personal cardiovascular medical history;
- Cardiovascular functional signs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with HFE hereditary haemochromatosis
The patients (40) will undergo a medical examination in order to analyse their medical history, cardiovascular parameters and check inclusion and non-inclusion criterions. Then will be performed :
|
Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP
Beta-hCG
Transthoracic echocardiograph
|
Experimental: Healthy volunteers
The healthy volunteers (10 men and 10 women) will undergo :
|
Transthoracic echocardiograph
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Myocardial T2* values in haemochromatosis compared to healthy volunteers
Time Frame: Day 1
|
Assessment of the percentage rate of patients presenting a lower T2* value than the baseline defined by the mean of T2* values measured in healthy volunteers with a 1 standard deviation margin.
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean T2 values in healthy volunteers and patients with HFE-related haemochromatosis
Time Frame: Day 1
|
Comparison of the mean T2 values in healthy volunteers and patients with HFE-related haemochromatosis
|
Day 1
|
Echocardiographic parameters of systolic and diastolic functions and myocardial deformation
Time Frame: Day 1
|
Day 1
|
|
Myocardial T2 and T2* values in both groups
Time Frame: Day 1
|
Day 1
|
|
Liver T2/T2* values
Time Frame: Day 1
|
Correlation between liver T2/T2* and myocardial T2/T2*
|
Day 1
|
Pancreas T2/T2* values
Time Frame: Day 1
|
Correlation between pancreas T2/T2* and myocardial T2/T2*
|
Day 1
|
Spleen T2/T2* values
Time Frame: Day 1
|
Correlation between spleen T2/T2* and myocardial T2/T2*
|
Day 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Erwan DONAL, MD, PhD, Rennes University Hospital - Service de cardiologie et maladies vasculaires
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-A01843-42
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Iron Overload
-
Novartis PharmaceuticalsCompletedTransfusional Iron OverloadItaly
-
ApoPharmaCompletedTransfusional Iron OverloadEgypt, Cyprus, Oman, Saudi Arabia, Turkey
-
Novartis PharmaceuticalsCompletedChronic Iron OverloadGermany
-
Novartis PharmaceuticalsNot yet recruiting
-
Novartis PharmaceuticalsCompletedCardiac Iron OverloadTaiwan, Egypt, Thailand, Turkey, United Kingdom, Italy, Canada, Greece
-
Assiut UniversityUnknownPlatelet Changes in Cases of Iron Overload
-
ApoPharmaCompletedIron Overload Due to Repeated Red Blood Cell TransfusionsUnited States, Canada, Greece, Italy
-
Assiut UniversityUnknownPlatelet Changes in Cases of Iron Overload
-
ShireTerminatedIron Overload Due to Repeated Red Blood Cell TransfusionsCanada, United States, Thailand, Italy, United Kingdom
-
ShireTerminatedPharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation TherapyIron Overload Due to Repeated Red Blood Cell TransfusionsUnited States, Canada, Lebanon, Italy, Egypt
Clinical Trials on 3Tesla cardiac MRI
-
University of FloridaOcala Royal DamesActive, not recruitingBreast CancerUnited States
-
AHS Cancer Control AlbertaCross Cancer InstituteCompleted
-
The University of Texas Health Science Center,...RecruitingSpastic DiplegiaUnited States
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI); Nationwide Children's Hospital and other collaboratorsCompletedPulmonary Hypertension | Congenital Heart Disease | Pediatric Congenital Heart DiseaseUnited States
-
Imperial College LondonNational Institute for Health Research, United Kingdom; Imperial College Healthcare...WithdrawnMyocardial Fibrosis | Heart Failure | End Stage Renal Failure on Dialysis | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe)United Kingdom
-
St. Jude Children's Research HospitalRecruitingSepsis | Acute Respiratory Distress Syndrome | Cardiovascular ShockUnited States
-
University Medical Center GoettingenNot yet recruitingTetralogy of Fallot | Congenital Heart DiseaseGermany
-
Cedars-Sinai Medical CenterRecruitingHealthyUnited States
-
Medical University of GrazEnrolling by invitationPulmonary Hypertension | Elevated Mean Pulmonary Arterial Pressure | Normal Mean Pulmonary Arterial PressureAustria
-
Cedars-Sinai Medical CenterNational Heart, Lung, and Blood Institute (NHLBI); University of Pittsburgh; University...Active, not recruitingCardiovascular DiseaseUnited States